6.9.6: 6. HPV-Related Oropharyngeal Cancer
- Page ID
- 53883
\( \newcommand{\vecs}[1]{\overset { \scriptstyle \rightharpoonup} {\mathbf{#1}} } \) \( \newcommand{\vecd}[1]{\overset{-\!-\!\rightharpoonup}{\vphantom{a}\smash {#1}}} \)\(\newcommand{\id}{\mathrm{id}}\) \( \newcommand{\Span}{\mathrm{span}}\) \( \newcommand{\kernel}{\mathrm{null}\,}\) \( \newcommand{\range}{\mathrm{range}\,}\) \( \newcommand{\RealPart}{\mathrm{Re}}\) \( \newcommand{\ImaginaryPart}{\mathrm{Im}}\) \( \newcommand{\Argument}{\mathrm{Arg}}\) \( \newcommand{\norm}[1]{\| #1 \|}\) \( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\) \( \newcommand{\Span}{\mathrm{span}}\) \(\newcommand{\id}{\mathrm{id}}\) \( \newcommand{\Span}{\mathrm{span}}\) \( \newcommand{\kernel}{\mathrm{null}\,}\) \( \newcommand{\range}{\mathrm{range}\,}\) \( \newcommand{\RealPart}{\mathrm{Re}}\) \( \newcommand{\ImaginaryPart}{\mathrm{Im}}\) \( \newcommand{\Argument}{\mathrm{Arg}}\) \( \newcommand{\norm}[1]{\| #1 \|}\) \( \newcommand{\inner}[2]{\langle #1, #2 \rangle}\) \( \newcommand{\Span}{\mathrm{span}}\)\(\newcommand{\AA}{\unicode[.8,0]{x212B}}\)
HPV-related Oropharyngeal cancer
- HPV 16 & 18 are associated with oropharyngeal cancer
- Sexually transmitted
- Mostly non-smoking, healthy young adults, more common males
- P16 is a surrogate marker for HPV (sensitivity 100%, has false +ves)
- May present with a small primary and large, often cystic, cervical metastases
- HPV status has prognostic value
- Different biological behaviour from tobacco-induced oropharyngeal cancer
- Better prognosis, even with advanced-stage disease
- Volume and extent of nodal metastases do not have same negative impact on outcome
- HPV + patients with a significant smoking history probably have same prognosis as HPV –
- Prognostic value of p16 status may not apply to suboptimally treated patients in resource constrained settings
- Affects staging
- Different N-staging for HPV+ vs HPV-
- Same T-staging for HPV+ and HPV-
- Stage IV only assigned to patients with distant metastases
- HPV status does not influence choice of primary treatment at this time